This site is intended for healthcare professionals
FDA Hero  Banner - Multi-coloured pills and tablets
FDA Drug information

TERUFLEX Blood Bag System Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1)

Read time: 3 mins
Marketing start date: 27 Apr 2024

Summary of product characteristics


Description

11. DESCRIPTION / PRODUCT SPECIFICATIONS 11.1. This blood bag system includes a 16 gauge x 1 1/2 inch (1.60 x 38 mm) needle with needle cover and either a 450 mL or 500 mL (nominal capacity 600 mL) primary collection bag containing 63 mL or 70 mL, respectively, Citrate Phosphate Dextrose Adenine (CPDA-1) anticoagulant, The Double blood bag set has one integrally attached empty satellite bag (nominal capacity 400 mL). The Triple blood bag set has one integrally attached empty satellite bag (nominal capacity 400 mL) and one empty XT-612 5 day Platelet bag (nominal capacity 500 mL). The Quadruple blood bag set has two integrally attached empty satellite bags (nominal capacity 400 mL) and one empty XT-612 5 day Platelet bag (nominal capacity 500 mL). 11.2. Blood bag codes ending in A4 are supplied with Integral Blood Sampling Arm for obtaining donor samples for laboratory testing after collection of the Whole Blood unit. 11.3. Blood bag codes ending in A3 also include a DonorCare Needle Guard pre-attached to the donor tubing. DonorCare Needle Guard device instructions are provided on the reverse side. 11.4. The blood bag collection set is made of PVC (polyvinyl chloride with DEHP plasticizer). 11.5. The blood bag has no components made of natural rubber latex. 11.6. Tubing internal diameter (ID) nominal 3.0 mm. 11.7. Tubing outer diameter (OD) nominal 4.4 mm. 11.8. Donor tubing line maximum 16 segments available.

Dosage And Administration

2. DOSAGE AND ADMINISTRATION 2.1. To open blister package, peel cover film back 4/5 of its length. 2.2. Prepare the blood bag following your institution's standard operating procedures. 2.2.1. Materials Needed: VENOJECT®@Tube Holder (code P-1316R) or equivalent VENOJECT@Multi-Sample Luer Adapter (code MN*2000T) or equivalent Evacuated blood collection tubes (glass or plastic) 2.3. Make a loose knot in the donor tubing below the "Y" unless alternate methods are used to seal the tubing at the end of collection. 2.4. Temporarily clamp donor tubing between the phlebotomy needle and the "Y". 2.5. Suspend the collection bag as far as possible below the donor's arm. 2.6. Apply blood pressure cuff or tourniquet to donor's arm. Disinfect site of phlebotomy according to institutional standard operating procedures. If blood pressure cuff is used, inflate to approximately 60 mmHg. 2.7. Remove the needle cover and perform phlebotomy. 2.7.1. CAUTION: Do not touch the needle after removing the needle cover. 2.8. Remove the temporary clamp on the donor tubing to permit blood flow into the collection bag. 2.9. If applicable, secure the needle safety device in place following the device instructions provided on the reverse side. 2.10. Secure donor tubing to donor's arm. 2.11. Mix blood with anticoagulant in the collection bag and continue to mix at several intervals during collection and immediately after collection. If using an automated mixer, follow manufacturer's instructions. 2.12. Collect labeled volume of blood 450 mL ±10% or 500 mL ±10%. 2.13. When the desired amount of blood has been collected, seal the tubing or tighten the loose knot (white knot) prepared in Step 2.3. Make a second seal between the first seal or knot and the "Y". Various methods may be used to seal tubing. 2.13.1. CAUTION: Do not use a dielectric tube sealer to seal the tubing while the needle is connected to the donor's body unless it is approved for such a purpose. 2.14. Anytime before Step # 2.19 below, sever donor tubing between the two seals. 2.15. Assemble the luer adapter and the tube holder. These steps may be performed before or during phlebotomy. 2.15.1. Connect the VENOJECT@Multi-Sample Luer Adapter to the VENOJECT@Tube Holder (or equivalent) (Fig. 1). 2.15.2. Remove covers and connect the multi-sample luer adapter to the female luer at end of Blood Sampling Arm (Fig. 2). 2.16. Collect blood samples as follows: 2.16.1. Break CLIKTIP ® (inline closure device) in the Blood Sampling Arm tubing to open blood pathway. 2.16.1.1. CAUTION: Do not break CLIKTIP until luer adapter/tube holder assembly is attached to the Blood Sampling Arm. 2.16.2. Insert blood collection tube firmly into the tube holder; when full, remove sample tube from holder. Repeat to collect additional samples. 2.17. Apply a clamp to the donor tubing between the phlebotomy needle and "Y"; release pressure on donor's arm and remove needle. If using a needle safety device, remove the needle into the needle safety device following the device instructions provided on the reverse side. 2.17.1. CAUTION: Discard the phlebotomy needle/donor tubing according to institutional standard operating procedures. 2.18. Immediately after collection, invert collection bag several times to assure blood and anticoagulant are well mixed. 2.19. Strip blood from donor tubing into collection bag, mix well, and allow tubing to refill; repeat once. To prevent the blood from clotting in the tubing, work quickly as possible. Make an appropriate number of segments of anticoagulated blood for testing by sealing on or near the X marks. Leave segments attached to Whole Blood unit. 2.20. The time between Whole Blood collection and component separation may vary depending on both the blood bag system and processing options selected. Follow your institution's standard operating procedures to prepare components. 2.20.1. If the Whole Blood is to be processed into room temperature components, maintain the blood at ambient temperature. 2.20.2. If the Whole Blood is to be processed into other components (including Plasma Frozen Within 24 Hours After Phlebotomy), Whole Blood must either be placed in storage at a temperature between 1-6°C within 8 hours of blood collection or cooled towards a temperature between 1-10°C (e.g. during transport) and then placed in storage at a temperature between 1-6°C upon arrival at the processing center. 2.21. Platelet Rich Plasma and Platelets should be separated from the Red Blood Cells within 8 hours of blood collection, if prepared. 2.22. Plasma intended for production of Fresh Frozen Plasma should be separated from the Red Blood Cells and placed in a freezer at –18°C or colder within 8 hours of blood collection. 2.23. Plasma intended for production of Plasma Frozen Within 24 Hours After Phlebotomy (PF24) should be placed in a freezer at –18°C or colder within 24 hours of blood collection. 2.24. For further preparation and processing of other plasma components, use standard processing and storage techniques following approved regulations and standards. 2.25. Select the appropriate spin condition and centrifuge Whole Blood unit to separate CPDA-1 Red Blood Cells from plasma or platelet rich plasma, as appropriate. 2.26. Break the CLIKTIP of primary collection bag and transfer plasma into satellite bag, or transfer platelet rich plasma into XT-612 ® Platelet bag. Clamp transfer tubing of satellite bag. 2.27. Seal tubing of primary collection bag in two places, cut between seals, and if applicable, separate from satellite bag(s). 2.28. Store CPDA-1 Red Blood Cells (or Whole Blood) between 1-6°C for up to 35 days. 2.29. If prepared, store Platelets between 20-24°C, maintaining a continuous gentle agitation, for up to 5 days in XT-612 bag.

Indications And Usage

FULL PRESCRIBING INFORMATION *Sections or subsections omitted from the Full Prescribing Information are not listed [includes sections 4, 6, 7, 8, 9, 10, 12, 13, 14, 15 and 17]. 1. INDICATIONS AND USAGE 1.1. Read these instructions carefully before use. 1.2. Rx ONLY. 1.3. Intended for the collection, processing and preservation of Whole Blood and blood components. Not intended for direct intravenous infusion. 1.4. For the collection of 450 mL ±10% or 500 mL ±10% Whole Blood. 1.5. Integral Blood Sampling Arm for obtaining donor samples for laboratory testing after collection of the Whole Blood unit. 1.6. For further processing, use standard component processing techniques. Image of Figure Sealing with tape Image of Fig. 1 (attach luer adapter to tube holder) Image of Fig. 2 (attach adapter/holder to Blood Sampling Arm)

Effective Time

20181207

Version

5

Dosage Forms And Strengths

3. DOSAGE FORMS AND STRENGTHS 3.1. 63 mL Citrate Phosphate Dextrose Adenine (CPDA-1) anticoagulant USP for collection of 450 mL Whole Blood. Each 63 mL contains 188 mg Citric Acid (anhydrous) USP, 1.66 g Sodium Citrate (dihydrate) USP, 140 mg Monobasic Sodium Phosphate (monohydrate) USP, 2.01 g Dextrose (monohydrate) USP and 17.3 mg Adenine USP. 3.2. 70 mL Citrate Phosphate Dextrose Adenine (CPDA-1) anticoagulant USP for collection of 500 mL Whole Blood. Each 70 mL contains 209 mg Citric Acid (anhydrous) USP, 1.84 g Sodium Citrate (dihydrate) USP, 155 mg Monobasic Sodium Phosphate (monohydrate) USP, 2.23 g Dextrose (monohydrate) USP and 19.3 mg Adenine USP.

Spl Product Data Elements

TERUFLEX Blood Bag System Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1) Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1) Anhydrous Citric Acid Anhydrous Citric Acid Trisodium Citrate Dihydrate Anhydrous Citric Acid SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE PHOSPHATE ION Dextrose Monohydrate Anhydrous Dextrose Adenine Adenine Water

Application Number

BN820528

Brand Name

TERUFLEX Blood Bag System Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1)

Generic Name

Anticoagulant Citrate Phosphate Dextrose Adenine (CPDA-1)

Product Ndc

53877-001

Product Type

HUMAN PRESCRIPTION DRUG

Route

INTRAVENOUS

Package Label Principal Display Panel

Tray/Case Label TERUFLEX® BLOOD BAG SYSTEM with Blood Sampling Arm TM ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA-1) USP FOR COLLECTION OF 500mL OF BLOOD Each unit consists of a primary bag containing 70 mL of solution with 209 mg Citric Acid (anhydrous) USP, 1.84 9 Sodium Citrate (dihydrate) USP, 155 mg Monobasic Sodium Phosphate (monohydrate) USP, 2.23 9 Dextrose (monohydrate) USP, 19.3 mg Adenine USP. STERILE, NON-PYROGENIC FLUID PATH. DO NOT USE UNLESS ANTICOAGULANT IS CLEAR. CODE LOT NO. EXPIRY UNITS DONOR NEEDLE 16G X 1 1/2" (1.60 X 38mm) RxONLY RECOMMENDED STORAGE: Room Temperature (15-30°C/59-86°F). Avoid excessive heat. Protect from freezing. After opening, unused bags may be stored for 30 days by returning cover film to original position and sealing with tape to prevent possible loss of moisture. See Instructions For Blood Collection. Manufactured by: TERUMO CORPORATION Tokyo, Japan ®: Registered Trademark Blood Sampling Arm is a trademark of TERUMO CORPORATION. Rev. 01/03 B-2-H6-A4-2 Image of Representative Tray/Case Label CPDA-1 500mL with BSA

Spl Unclassified Section

Revised 2015-12 N-BB-CA-A(SP) 5 CPDA-1 SOLUTION For the collection of 450 mL or 500 mL of Whole Blood

How Supplied

16. HOW SUPPLIED/STORAGE AND HANDLING 16.1. Single use only. 16.2. Sterile and non-pyrogenic fluid path. Sterilized by steam. Opacity of the blood bag system may be observed. This is due to moisture absorption during the sterilization process. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. 16.3. A Material Safety Data Sheet (MSDS) is not required for this product. 16.4. Recommended storage conditions: Room Temperature (15-30°C/59-86°F). 16.5. Avoid excessive heat and direct sunlight. Protect from freezing. 16.6. To open blister package, peel cover film back 4/5 of its length. 16.7. After opening the blister package, unused blood bags may be stored at room temperature for 96 hours or they may be stored for 30 days by returning cover film to original position and sealing with tape to prevent evaporation of solutions. 16.8. Blood bags in the unopened blister package may be used through the last day of the month and year as indicated on the original manufacturer's packaging. 16.9. The AGELESS packet contained in this package absorbs oxygen and generates heat on removal. Do not open and handle it with care. 16.10. Dispose of the AGELESS packet with the blister tray. 16.11. Do not dispose the AGELESS packet with wastes containing volatile or flammable materials. 16.12. For the Single blood bag sets, Codes BB*SCD456A3 and BB*SCD506A3 are supplied 36/case, Code BB*SCD456A4 is supplied 48/case. 16.13. For the Double blood bag sets, Codes BB*DCD456A3 , BB*DCD456A4 and BB*DCD506A3 are supplied 30/case. 16.14. For the Triple blood bag sets, Codes BB*TCD456A3 and BB*TCD456A4 are supplied 30/case. 16.15. For the Quadruple blood bag sets, Codes BB*QCD456A3 and BB*QCD506A3 are supplied 24/case. MANUFACTURED BY: TERUMO CORPORATION 44-1, 2-CHOME, HATAGAYA, SHIBUYA-KU, TOKYO 151-0072, JAPAN MADE IN JAPAN (R): Registered Trademark ©TERUMO CORPORATION December, 2015 DonorCare is a registered trademark of Noble House Group Pty. Ltd. CORPORATION. AGELESS is a registered trademark of MITSUBISHI GAS CHEMICAL CO., INC.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.